Daewoong Pharmaceutical: Cleancall Tablets Phase 3 Results Published in WJG, Adverse Reactions Reduced

Comparable Efficacy Achieved with Fewer Tablets Than Existing Products

"Delivers Both Performance and Safety in Bowel Preparation"

Daewoong Pharmaceutical announced on March 4 that the results of the Phase 3 clinical trial for its next-generation tablet-type bowel preparation, Cleancall Tablets, have been published in the SCI-grade international journal in the field of digestive diseases, the World Journal of Gastroenterology.

Daewoong Pharmaceutical’s Cleancall Tablets are characterized by a 25% reduction in sulfate content compared to existing products and a decreased number of tablets required for administration (20 tablets), thereby reducing the burden on patients. The product has also been developed with the addition of picosulfate, an ingredient that helps facilitate bowel movements, enabling excellent bowel cleansing efficacy with a smaller dosage.

Daewoong Pharmaceutical Cleancall Tablets. Daewoong Pharmaceutical

This paper is based on the results of a multicenter, randomized, Phase 3 clinical trial conducted on 215 adults across seven university hospitals in Korea. The study employed a single-blind, parallel-group, active-controlled, non-inferiority design and evaluated colonoscopy images.

The study found that Cleancall Tablets maintained a comparable level of bowel cleansing efficacy to existing bowel preparations, despite reducing the number of tablets to 20. The overall incidence rate of adverse drug reactions was significantly lower for Cleancall Tablets (18.10%) compared to existing bowel preparations (33.02%). Nausea and headache also showed significant differences in favor of Cleancall Tablets.

Dongil Park, Professor at Kangbuk Samsung Hospital and principal investigator of the study, stated, "Cleancall Tablets demonstrated clinically sufficient bowel cleansing efficacy and excellent safety, even at a lower dosage compared to conventional oral sulfate solution (OSS) products. We expect it will help reduce the burden on patients and improve medication compliance during colonoscopy preparation."

Hyungchul Park, Head of ETC Marketing Division at Daewoong Pharmaceutical, said, "Cleancall Tablets are a next-generation bowel preparation that resolves the biggest concern for patients during colonoscopy preparation—the dosage—while providing the required clinical performance and safety. With this publication in an international academic journal, we expect Cleancall Tablets to become an important option for colonoscopy preparation."

This content was produced with the assistance of AI translation services.